[{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Urology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Urology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Urology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Urology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Urology","graph2":"Phase IV","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wake Forest University Health Sciences \/ Allergan","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University Health Sciences \/ Allergan"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Urology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Xintian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Silodosin","moa":"Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Xintian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xintian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Xintian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Silodosin","moa":"Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Chonnam National University Hospital | Kangdong Sacred Heart Hospital | Yeungnam University Hospital | Pusan National University Hospital | Seoul National University Hospital | Samsung Medical Center | Seoul St. Mary's Hospital | Korea University Guro Hos","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Silodosin","moa":"Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical \/ Chonnam National University Hospital | Kangdong Sacred Heart Hospital | Yeungnam University Hospital | Pusan National University Hospital | Seoul National University Hospital | Samsung Medical Center | Seoul St. Mary's Hospital | Korea University Guro Hos","highestDevelopmentStatusID":"11","companyTruncated":"JW Pharmaceutical \/ Chonnam National University Hospital | Kangdong Sacred Heart Hospital | Yeungnam University Hospital | Pusan National University Hospital | Seoul National University Hospital | Samsung Medical Center | Seoul St. Mary's Hospital | Korea University Guro Hos"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Silodosin","moa":"Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Silodosin","moa":"Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"JW Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Huilun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Silodosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Shanghai Huilun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Huilun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Huilun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ITALY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Silodosin","moa":"Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Albert Einstein Healthcare Network","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Silodosin","moa":"Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Albert Einstein Healthcare Network","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albert Einstein Healthcare Network \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Albert Einstein Healthcare Network \/ Undisclosed"},{"orgOrder":0,"company":"Biocinese","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Biocinese","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocinese \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Biocinese \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"PAKISTAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Astellas Pharma | Medical Research Collaborating Center, Seoul, Korea","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seoul National University Hospital \/ Astellas Pharma | Medical Research Collaborating Center, Seoul, Korea","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Astellas Pharma | Medical Research Collaborating Center, Seoul, Korea"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Ascension Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Ascension Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascension Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ascension Health \/ Undisclosed"},{"orgOrder":0,"company":"Anand Rughani, MD","sponsor":"MaineHealth","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Anand Rughani, MD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anand Rughani, MD \/ MaineHealth","highestDevelopmentStatusID":"11","companyTruncated":"Anand Rughani, MD \/ MaineHealth"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"NeoTract, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"NeoTract, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeoTract, Inc. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NeoTract, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Naftopidil","moa":"Alpha-1d adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Dong-A Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Ertapenem","moa":"Bacterial penicillin-binding protein","graph1":"Urology","graph2":"Phase IV","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Merck & Co"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Endeavor Health | Case Western Reserve University","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Metoprolol Tartrate","moa":"Beta-1 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virginia Commonwealth University \/ Endeavor Health | Case Western Reserve University","highestDevelopmentStatusID":"11","companyTruncated":"Virginia Commonwealth University \/ Endeavor Health | Case Western Reserve University"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Loyola University","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Loyola University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loyola University \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Loyola University \/ Astellas Pharma"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Undisclosed"},{"orgOrder":0,"company":"State University of New York at Buffalo","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"State University of New York at Buffalo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"State University of New York at Buffalo \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"State University of New York at Buffalo \/ Astellas Pharma"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Nova Scotia Health Authority \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Nova Scotia Health Authority \/ Undisclosed"},{"orgOrder":0,"company":"Dawnrays Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"HONG KONG","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Potassium Citrate","moa":"Calcium","graph1":"Urology","graph2":"Phase IV","graph3":"Dawnrays Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dawnrays Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dawnrays Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"QATAR","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Diclofenac","moa":"Cyclooxygenase","graph1":"Urology","graph2":"Phase IV","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Urology","graph2":"Phase IV","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"Citrus Valley Medical Research, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Urology","graph2":"Phase IV","graph3":"Citrus Valley Medical Research, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Citrus Valley Medical Research, Inc. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Citrus Valley Medical Research, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Loyola University","sponsor":"KIMBERLY CLARK HEALTH CARE","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Estradiol","moa":"estrogens","graph1":"Urology","graph2":"Phase IV","graph3":"Loyola University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Loyola University \/ KIMBERLY CLARK HEALTH CARE","highestDevelopmentStatusID":"11","companyTruncated":"Loyola University \/ KIMBERLY CLARK HEALTH CARE"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Urofollitropin","moa":"Follicle stimulating hormone receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"AJU Pharm","sponsor":"Om Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"OM-89","moa":"Immune","graph1":"Urology","graph2":"Phase IV","graph3":"AJU Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AJU Pharm \/ Om Pharma","highestDevelopmentStatusID":"11","companyTruncated":"AJU Pharm \/ Om Pharma"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fesoterodine","moa":"Muscarinic acetylcholine receptor M2||Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Pfizer Inc"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fesoterodine","moa":"Muscarinic acetylcholine receptor M2||Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase IV","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Cleveland Clinic \/ Pfizer Inc"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fesoterodine","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fesoterodine","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fesoterodine","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fesoterodine","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fesoterodine","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cantonal Hospital, Frauenfeld","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Cantonal Hospital, Frauenfeld","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cantonal Hospital, Frauenfeld \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Cantonal Hospital, Frauenfeld \/ Astellas Pharma"},{"orgOrder":0,"company":"Loyola University","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Loyola University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loyola University \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Loyola University \/ Astellas Pharma"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tolterodine Tartrate","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ITALY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Gel","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Trospium Chloride","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Trospium Chloride","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Kyorin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imidafenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase IV","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Life Sciences \/ Kyorin Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"LG Life Sciences \/ Kyorin Pharmaceutical"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Astellas Pharma | Beijing CAT Science","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Peking Union Medical College Hospital \/ Astellas Pharma | Beijing CAT Science","highestDevelopmentStatusID":"11","companyTruncated":"Peking Union Medical College Hospital \/ Astellas Pharma | Beijing CAT Science"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Indigo Carmine","moa":"None","graph1":"Urology","graph2":"Phase IV","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provepharm Life Solutions \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Provepharm Life Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Indigo Carmine","moa":"None","graph1":"Urology","graph2":"Phase IV","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provepharm Life Solutions \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Provepharm Life Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Provepharm Life Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Indigo Carmine","moa":"None","graph1":"Urology","graph2":"Phase IV","graph3":"Provepharm Life Solutions","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provepharm Life Solutions \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Provepharm Life Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Urology","graph2":"Phase IV","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Florence","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Urology","graph2":"Phase IV","graph3":"University of Florence","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"University of Florence \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"University of Florence \/ Eli Lilly"},{"orgOrder":0,"company":"TriHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Urology","graph2":"Phase IV","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Solution","sponsorNew":"TriHealth \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"TriHealth \/ Undisclosed"},{"orgOrder":0,"company":"TriHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Urology","graph2":"Phase IV","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Solution","sponsorNew":"TriHealth \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"TriHealth \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Urology","graph2":"Phase IV","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Urology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Urology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Urology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Urology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Urology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Urology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Urology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Urology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Urology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Urology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Urology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Urology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Urotronic Inc.","sponsor":"Laborie Medical Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Urology","graph2":"Phase IV","graph3":"Urotronic Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Urotronic Inc. \/ Laborie Medical Technologies","highestDevelopmentStatusID":"11","companyTruncated":"Urotronic Inc. \/ Laborie Medical Technologies"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Cyclic Microgestin","moa":"Undisclosed","graph1":"Urology","graph2":"Phase IV","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Endeavor Health \/ National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"11","companyTruncated":"Endeavor Health \/ National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Xintian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Ningmitai","moa":"Undisclosed","graph1":"Urology","graph2":"Phase IV","graph3":"Xintian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xintian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Xintian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Xintian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Ningmitai","moa":"Undisclosed","graph1":"Urology","graph2":"Phase IV","graph3":"Xintian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xintian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Xintian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Xintian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Ningmitai","moa":"Undisclosed","graph1":"Urology","graph2":"Phase IV","graph3":"Xintian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xintian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Xintian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Xintian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Ningmitai","moa":"Undisclosed","graph1":"Urology","graph2":"Phase IV","graph3":"Xintian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xintian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Xintian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chemical Resources","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Prunus Domestica Extract","moa":"Undisclosed","graph1":"Urology","graph2":"Phase IV","graph3":"Chemical Resources","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chemical Resources \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chemical Resources \/ Undisclosed"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"AUSTRALIA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Saw Palmetto Extract","moa":"Undisclosed","graph1":"Urology","graph2":"Phase IV","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RDC Clinical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"RDC Clinical \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Serenoa Repens Extract","moa":"Undisclosed","graph1":"Urology","graph2":"Phase IV","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Serenoa Repens Extract","moa":"Undisclosed","graph1":"Urology","graph2":"Phase IV","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Herbarium Laboratorio Botanico","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Tribulus Terrestris","moa":"Undisclosed","graph1":"Urology","graph2":"Phase IV","graph3":"Herbarium Laboratorio Botanico","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Herbarium Laboratorio Botanico \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Herbarium Laboratorio Botanico \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"BELGIUM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Phase IV","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Ghent \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital Ghent \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Timothy Boone, MD, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Timothy Boone, MD, PhD","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Timothy Boone, MD, PhD"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"St\u00e9phane Bolduc","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fesoterodine","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ St\u00e9phane Bolduc","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ St\u00e9phane Bolduc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"St\u00e9phane Bolduc","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Fesoterodine","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ St\u00e9phane Bolduc","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ St\u00e9phane Bolduc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Jeong Gu Lee","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Jeong Gu Lee","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Jeong Gu Lee"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
